No historical price data available
No price history data available for the selected time period.
Try selecting a different time range.
Company Overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Company Information
- CEO
- Matthew Pauls
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
Contact Information
- Website
- https://www.savarapharma.com
- Address
- Building III
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 459.75M market capitalization
- Trading Volume: 2.78M shares traded today
- Price Range: 52-week range of $1.89 - $4.74
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Savara Inc.
Savara Inc. (SVRA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 459.75M, the company represents a significant player in its market. The stock is currently trading at $2.66 with a positivedaily change of 3.10%.
The company's 59 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -5.43, beta of 0.31, and 52-week price range from $1.89 to $4.74when evaluating investment opportunities.
Why Invest in Savara Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Matthew Pauls
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential